Developer docs
API playgroundTry for free, no card

Search company profiles

Black Arrow Biotech Inc.

Full company profile

uuid02f4tus

Namestring
Black Arrow Biotech Inc.
Legal namestring
Black Arrow Biotech OÜ
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Black Arrow Biotech OÜ is an Estonian-headquartered private company founded in 2024 that develops AI-driven tools and assets for peptide-based drug discovery. Its core product is JÜRI, a proprietary AI platform that performs generative peptide design, predictive screening of peptide sequences ranging from 5 to 50 amino acids, and toxicity classification including haemolytic properties. The company claims JÜRI operates more than 45 times faster than human expert teams and learns continuously from each engagement. Around JÜRI, Black Arrow offers three commercial surfaces: a fee-for-service Peptide Screening product with a 14-day typical turnaround; AI-derived Peptide Libraries sold with extensive customization (10 to 100,000 peptides, 5 to 40 amino acids, 1 to 100 mg, purity bands from >70% to >95%); and an internal drug pipeline anchored by BAC2539, an RNA therapeutic producing an anti-cancer peptide with a guidance and activation system. The company's primary customers are pharmaceutical and biotech researchers, supplemented by academic institutions, and it operates a sales-led, direct B2B motion with contact-based quoting. The only publicly disclosed customer outcome is a collaboration with the Department of Pharmacology at Democritus University of Thrace, where nine AI-derived anti-cancer peptides were tested against A549 lung cancer cells and two advanced to further testing. Black Arrow is founder-owned, has six named leaders across CEO, CTO, CBIO, CSO, COO, and SPM functions, and runs offices in Tallinn, Estonia and Caulfield, Australia.

Short descriptiontext

Black Arrow Biotech is an Estonian private company that builds the JÜRI AI platform for generative peptide design, screening, and library curation, selling fee-for-service tools and AI-derived peptide assets to pharmaceutical, biotech, and academic drug discovery researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTallinn, Estonia
HQ citystring
Tallinn
HQ countrystring
Estonia
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI peptide discovery, drug discovery platform, peptide screening services, machine learning therapeutics, bioinformatics drug development
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI-Driven Peptide Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Peptide Screening Services
TypeProfessional Services
Description

Fee-for-service solution where customers submit peptides (5-50 amino acids) for AI-driven screening with JÜRI. Customers receive detailed reports including peptide properties, statistical significance, accuracy and specificity metrics. Typical turnaround time is 14 days.

blackarrowbio.tech
2Peptide Library Sales
TypeOne Time License
Description

Sale of customized AI-derived peptide libraries with various options including peptide count (10 to 100,000), length (5-40 amino acids), quantity (1mg to 100mg), and purity levels (>70%, >80%, >90%, >95%). Libraries are available in multiple forms including powder, solution, coated plates, and with cleavable/non-cleavable options.

blackarrowbio.tech
3Drug Development Pipeline
TypeLicensing Royalties
Description

Proprietary drug development using JÜRI for internal drug discovery, with the first drug candidate BAC2539 (an RNA drug producing anti-cancer peptide) in their pipeline for cancer treatment.

blackarrowbio.tech
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details2 tiers
1Peptide Screening Service
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Fee-for-service solution with typical turnaround time of 14 days. Customers submit peptides and specify biological activity for AI screening.

blackarrowbio.tech
2Custom Peptide Libraries
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Customized peptide libraries with options: peptide count (10-100,000), amino acid length (5-40), quantity (1-100mg), and purity (>70%, >80%, >90%, >95%). Preparation and delivery takes approximately 6-8 weeks.

blackarrowbio.tech
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1JÜRI
Description

AI-powered peptide screening and generation platform that accelerates drug discovery by identifying potential therapeutic candidates.

blackarrowbio.tech
Core offering1 text field

Black Arrow Biotech develops and operates JÜRI, an AI platform that screens and generates therapeutic peptides, and sells AI-driven peptide discovery services to pharmaceutical and biotech researchers. Commercial offerings include fee-for-service peptide screening (5–50 amino acids, ~14-day turnaround), customized AI-derived peptide libraries, and an internal drug development pipeline (lead candidate BAC2539, an RNA drug producing anti-cancer peptide). The company also licenses its underlying AI capability for downstream drug discovery applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 45x faster peptide analysis compared to human expert teams
+4 more records
Product overview1 text field

Black Arrow Biotech offers a unified platform of AI-powered peptide drug discovery services centered around their proprietary AI platform JÜRI. The portfolio includes: JÜRI (core AI engine for peptide generation and screening), Peptide Screening (fee-for-service analysis of 5-50 amino acid peptides), Peptide Libraries (AI-derived catalogues across cancer, anti-infective, neurological, metabolic and cosmetic categories), and BAC2539 (lead drug candidate in pipeline). These offerings work together as an integrated drug discovery ecosystem—from AI-driven peptide generation through screening, library selection, and therapeutic development.

Product and service4 records
1JÜRI AI Platform
CategoryAI Drug Discovery Software
Description

Leading-edge AI platform designed to revolutionize peptide screening and generation. JÜRI accelerates drug discovery by identifying potential therapeutic candidates more efficiently than traditional methods, capable of working more than 45x faster than human experts. It uses generative AI, machine learning, and computer-aided design to move from random peptide libraries to physical drug candidates with high likelihood of safety and effectiveness.

2Peptide Screening Service
CategoryDrug Discovery Services
Description

AI-driven fee-for-service platform that streamlines peptide screening, analyzing peptide sequences ranging from 5–50 amino acids with advanced algorithms to identify and optimize peptides for targeted therapeutic applications. Customers submit peptides and receive detailed reports with accuracy, specificity, and statistical significance metrics, validated against known positive and negative cases.

3Custom Peptide Libraries
CategoryReagent Products
Description

AI-derived peptide catalogues for high-throughput screening, meticulously curated using generative AI, machine learning, and computer-aided design. Includes diverse collections across Drug Delivery, Neurological, Anti-Infective, Metabolic Disease, Cancer, and Cosmetic categories, with configurable peptide count, length, quantity, and purity.

4BAC2539 (Drug Pipeline Candidate)
CategoryDrug Pipeline Candidates
Description

First drug candidate in Black Arrow Biotech's development pipeline; an RNA drug that produces a potent anti-cancer peptide with a guidance and activation system intended for the treatment of various types of cancer.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US generative AI company designing de novo antibodies and other biologics with a wet-lab loop; overlaps with Black Arrow's generative AI biologics positioning but focuses on antibodies rather than therapeutic peptides.

TypeDirect peer
Description

US-based AI-driven peptide therapeutics company combining a platform with an internal clinical-stage pipeline; closely mirrors Black Arrow's services-plus-pipeline dual strategy in the peptide modality.

3Iambic Therapeutics
TypeEmerging player
Description

US AI-driven drug discovery company combining a discovery platform with an internal clinical-stage pipeline; comparable in stage and approach but with broader modality scope than Black Arrow's peptide focus.

4Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company building a multi-modality discovery engine; well-capitalized incumbent whose expansion into biologics directly threatens smaller AI-discovery startups pitching into the same pharma accounts.

TypeBroad incumbent
Description

Global AI drug discovery company operating both an internal pipeline and a Pharma.AI partnership platform; broader target across small molecules and biologics but a key competitor for AI-driven discovery deals with enterprise pharma.

TypeDirect peer
Description

Israel-based AI peptide drug design company that uses computational methods to discover peptide therapeutics; one of the closest direct comparables to Black Arrow's JÜRI platform approach in terms of target modality (peptides) and AI-led discovery model.

TypeEmerging player
Description

UK AI-driven antibody engineering company that combines ML with automated experimentation; comparable in AI-for-biologics approach and B2B platform model but focused on antibody rather than peptide discovery.

TypeBroad incumbent
Description

Well-funded US generative biology company creating novel protein therapeutics using AI; broader scope across protein modalities but a direct competitor for AI-designed biologic discovery partnerships with large pharma.

TypeDirect peer
Description

Dutch generative AI company engineering proteins and peptides with a B2B services and partnerships model; competes head-on with JÜRI in computational biologics design and serves a similar pharma/biotech research customer base.

TypeEmerging player
Description

UK AI-immunology company designing TCR and antibody therapeutics using ML; comparable as an AI-engineered biologics platform serving pharma research, though narrower in target class than Black Arrow's peptide libraries.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Black Arrow Biotech Inc.

AI-Driven Peptide Drug Discoveryblackarrowbio.tech

Black Arrow Biotech is an Estonian private company that builds the JÜRI AI platform for generative peptide design, screening, and library curation, selling fee-for-service tools and AI-derived peptide assets to pharmaceutical, biotech, and academic drug discovery researchers.

What Black Arrow Biotech Inc. does

Black Arrow Biotech OÜ is an Estonian-headquartered private company founded in 2024 that develops AI-driven tools and assets for peptide-based drug discovery. Its core product is JÜRI, a proprietary AI platform that performs generative peptide design, predictive screening of peptide sequences ranging from 5 to 50 amino acids, and toxicity classification including haemolytic properties. The company claims JÜRI operates more than 45 times faster than human expert teams and learns continuously from each engagement. Around JÜRI, Black Arrow offers three commercial surfaces: a fee-for-service Peptide Screening product with a 14-day typical turnaround; AI-derived Peptide Libraries sold with extensive customization (10 to 100,000 peptides, 5 to 40 amino acids, 1 to 100 mg, purity bands from >70% to >95%); and an internal drug pipeline anchored by BAC2539, an RNA therapeutic producing an anti-cancer peptide with a guidance and activation system. The company's primary customers are pharmaceutical and biotech researchers, supplemented by academic institutions, and it operates a sales-led, direct B2B motion with contact-based quoting. The only publicly disclosed customer outcome is a collaboration with the Department of Pharmacology at Democritus University of Thrace, where nine AI-derived anti-cancer peptides were tested against A549 lung cancer cells and two advanced to further testing. Black Arrow is founder-owned, has six named leaders across CEO, CTO, CBIO, CSO, COO, and SPM functions, and runs offices in Tallinn, Estonia and Caulfield, Australia.

Black Arrow Biotech Inc. firmographics

Firmographics
Name
Black Arrow Biotech Inc.
Legal name
Black Arrow Biotech OÜ
Website
https://blackarrowbio.tech
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Black Arrow Biotech is an Estonian private company that builds the JÜRI AI platform for generative peptide design, screening, and library curation, selling fee-for-service tools and AI-derived peptide assets to pharmaceutical, biotech, and academic drug discovery researchers.
Ownership category
akta.pro rank

Black Arrow Biotech Inc. industry classification

Industry
Product category
AI-Driven Peptide Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • AI peptide discovery
  • Drug discovery platform
  • Peptide screening services
  • Machine learning therapeutics
  • Bioinformatics drug development

Where Black Arrow Biotech Inc. is headquartered

Location

Headquarters

HQ city
Tallinn
HQ country
Estonia
HQ region
Europe

Offices2 records

Markets served

Black Arrow Biotech Inc. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Peptide Screening Services: Fee-for-service solution where customers submit peptides (5-50 amino acids) for AI-driven screening with JÜRI. Customers receive detailed reports including peptide properties, statistical significance, accuracy and specificity metrics. Typical turnaround time is 14 days.
  2. Peptide Library Sales: Sale of customized AI-derived peptide libraries with various options including peptide count (10 to 100,000), length (5-40 amino acids), quantity (1mg to 100mg), and purity levels (>70%, >80%, >90%, >95%). Libraries are available in multiple forms including powder, solution, coated plates, and with cleavable/non-cleavable options.
  3. Drug Development Pipeline: Proprietary drug development using JÜRI for internal drug discovery, with the first drug candidate BAC2539 (an RNA drug producing anti-cancer peptide) in their pipeline for cancer treatment.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPeptide Screening Service
Unit PricingMulti-year contractCustom Peptide Libraries

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Black Arrow Biotech Inc. product offering

Product offering

Core offering

Black Arrow Biotech develops and operates JÜRI, an AI platform that screens and generates therapeutic peptides, and sells AI-driven peptide discovery services to pharmaceutical and biotech researchers. Commercial offerings include fee-for-service peptide screening (5–50 amino acids, ~14-day turnaround), customized AI-derived peptide libraries, and an internal drug development pipeline (lead candidate BAC2539, an RNA drug producing anti-cancer peptide). The company also licenses its underlying AI capability for downstream drug discovery applications.

Product overview

Black Arrow Biotech offers a unified platform of AI-powered peptide drug discovery services centered around their proprietary AI platform JÜRI. The portfolio includes: JÜRI (core AI engine for peptide generation and screening), Peptide Screening (fee-for-service analysis of 5-50 amino acid peptides), Peptide Libraries (AI-derived catalogues across cancer, anti-infective, neurological, metabolic and cosmetic categories), and BAC2539 (lead drug candidate in pipeline). These offerings work together as an integrated drug discovery ecosystem—from AI-driven peptide generation through screening, library selection, and therapeutic development.

Differentiator

Problem solved

Functional benefit

Brands

  • JÜRI: AI-powered peptide screening and generation platform that accelerates drug discovery by identifying potential therapeutic candidates.

Products and services

  • JÜRI AI Platform Leading-edge AI platform designed to revolutionize peptide screening and generation. JÜRI accelerates drug discovery by identifying potential therapeutic candidates more efficiently than traditional methods, capable of working more than 45x faster than human experts. It uses generative AI, machine learning, and computer-aided design to move from random peptide libraries to physical drug candidates with high likelihood of safety and effectiveness.
  • Peptide Screening Service AI-driven fee-for-service platform that streamlines peptide screening, analyzing peptide sequences ranging from 5–50 amino acids with advanced algorithms to identify and optimize peptides for targeted therapeutic applications. Customers submit peptides and receive detailed reports with accuracy, specificity, and statistical significance metrics, validated against known positive and negative cases.
  • Custom Peptide Libraries AI-derived peptide catalogues for high-throughput screening, meticulously curated using generative AI, machine learning, and computer-aided design. Includes diverse collections across Drug Delivery, Neurological, Anti-Infective, Metabolic Disease, Cancer, and Cosmetic categories, with configurable peptide count, length, quantity, and purity.
  • BAC2539 (Drug Pipeline Candidate) First drug candidate in Black Arrow Biotech's development pipeline; an RNA drug that produces a potent anti-cancer peptide with a guidance and activation system intended for the treatment of various types of cancer.

Quantifiable outcome

  • 45x faster peptide analysis compared to human expert teams
  • +4 more outcomes

Companies that use Black Arrow Biotech Inc.

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Black Arrow Biotech Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Black Arrow Biotech Inc. partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Black Arrow Biotech Inc. competitors and assessment

Company assessment

Emerging players

  • Absci: US generative AI company designing de novo antibodies and other biologics with a wet-lab loop; overlaps with Black Arrow's generative AI biologics positioning but focuses on antibodies rather than therapeutic peptides.
  • Iambic Therapeutics: US AI-driven drug discovery company combining a discovery platform with an internal clinical-stage pipeline; comparable in stage and approach but with broader modality scope than Black Arrow's peptide focus.
  • LabGenius: UK AI-driven antibody engineering company that combines ML with automated experimentation; comparable in AI-for-biologics approach and B2B platform model but focused on antibody rather than peptide discovery.
  • Etcembly: UK AI-immunology company designing TCR and antibody therapeutics using ML; comparable as an AI-engineered biologics platform serving pharma research, though narrower in target class than Black Arrow's peptide libraries.

Direct peers

  • Peptilogics: US-based AI-driven peptide therapeutics company combining a platform with an internal clinical-stage pipeline; closely mirrors Black Arrow's services-plus-pipeline dual strategy in the peptide modality.
  • Pepticom: Israel-based AI peptide drug design company that uses computational methods to discover peptide therapeutics; one of the closest direct comparables to Black Arrow's JÜRI platform approach in terms of target modality (peptides) and AI-led discovery model.
  • Cradle: Dutch generative AI company engineering proteins and peptides with a B2B services and partnerships model; competes head-on with JÜRI in computational biologics design and serves a similar pharma/biotech research customer base.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company building a multi-modality discovery engine; well-capitalized incumbent whose expansion into biologics directly threatens smaller AI-discovery startups pitching into the same pharma accounts.
  • Insilico Medicine: Global AI drug discovery company operating both an internal pipeline and a Pharma.AI partnership platform; broader target across small molecules and biologics but a key competitor for AI-driven discovery deals with enterprise pharma.
  • Generate Biomedicines: Well-funded US generative biology company creating novel protein therapeutics using AI; broader scope across protein modalities but a direct competitor for AI-designed biologic discovery partnerships with large pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Black Arrow Biotech Inc. social profiles

Digital presence

Black Arrow Biotech Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Black Arrow Biotech Inc. leadership team

Management profile

Number of profiles

Profiles6 records

Black Arrow Biotech Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Black Arrow Biotech Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Black Arrow Biotech Inc.

What does Black Arrow Biotech Inc. do?

Black Arrow Biotech develops and operates JÜRI, an AI platform that screens and generates therapeutic peptides, and sells AI-driven peptide discovery services to pharmaceutical and biotech researchers. Commercial offerings include fee-for-service peptide screening (5–50 amino acids, ~14-day turnaround), customized AI-derived peptide libraries, and an internal drug development pipeline (lead candidate BAC2539, an RNA drug producing anti-cancer peptide). The company also licenses its underlying AI capability for downstream drug discovery applications.

Is Black Arrow Biotech Inc. a public or private company?

Black Arrow Biotech Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Black Arrow Biotech Inc. founded?

Black Arrow Biotech Inc. was founded in 2024. It employs 1 to 10 people.

Where is Black Arrow Biotech Inc. based?

Black Arrow Biotech Inc. is headquartered in Tallinn, Estonia, in the Europe region.

How does Black Arrow Biotech Inc. make money?

Three revenue lines are on record. Peptide Screening Services are the primary driver. The others are peptide Library Sales and drug Development Pipeline.

Who are Black Arrow Biotech Inc.'s main competitors?

Emerging players on record are Absci, Iambic Therapeutics, LabGenius and Etcembly. Direct peers are Peptilogics, Pepticom and Cradle. Broad incumbents are Isomorphic Labs, Insilico Medicine and Generate Biomedicines.

Does Black Arrow Biotech Inc. have an API?

No public API is recorded for Black Arrow Biotech Inc..

What industry is Black Arrow Biotech Inc. in?

Black Arrow Biotech Inc.'s product category is AI-Driven Peptide Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales